About this event

  • Date and time Tue 27 Jul 2021 from 6:00pm to 7:00pm
  • Location Online
  • Organised by Oncology

Effective management of adverse events is critical for both patients’ outcome and their quality of life. This webinar seeks to provide a tumour agnostic educational tool on the effective management of adverse events with immunotherapy combinations.

This meeting is fully funded by Eisai and is non-promotional. Content and speakers were chosen by the company. The meeting is intended for healthcare professionals only.

Date of preparation: July2021 UK-ONC-21-00065

During this session, participants will be able to:

  • Learn about the gained experience with managing adverse events associated with immunotherapy/immunotherapy combinations
  • Be able to identify types of adverse events more associated with targeted/TKI therapy vs those more associated with immunotherapy

A CPD certificate with 1 CPD credit will be issued to those joining the webinar live as well as those who watch the recording afterwards. Certificates will be issued 7 days after the webinar to those who watch it live and after 30 days for those that watch the recording.

This webinar is available for on-demand viewing. The webinar recording will be available for registered delegates up to 30 days after the live webinar broadcast via Zoom. The link will be sent 24 hours after the webinar takes place. 

Join in the conversation online #RSMLive
Follow us on Twitter: @RoySocMed 

Tickets

Standard pricing available until 27 July 2021.

Member

RSM Member
£0.00

Non - Member

Non - Member
£0.00

Key speakers

Chair: Dr David Pinato

Clinical Senior Lecturer and Consultant Medical Oncologist, Chief Investigator of the OnCovid Study, Imperial College London

Speaker's biography
Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working within the Department of Surgery and Cancer at Imperial College, London.
Dr Pinato leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented David’s focus of research since graduation with the highest honours at the University of Piemonte Orientale "A. Avogadro" in Novara, Italy. In 2018 David was awarded a Clinician Scientist fellowship funded by the Wellcome Trust Strategic Fund centred on the development of immunotherapy in liver cancer. Hepatocellular Carcinoma (HCC) is the most frequently occurring primary liver tumour that currently ranks 5th by incidence and 3rd by mortality on a global scale.

Expert panel: Dr Alessio Cortellini

Consultant Medical Oncologist University L'Aquila, Italy and Imperial College Hospital, London, Visiting Reseracher Imperial College Hospital London

Speaker's biography
Dr Alessio Cortellini is a consultant medical oncologist and clinical scientist with a special interest in the immunotherapy of cancer. He graduated with honours at the University of L’Aquila in Italy, where he also completed his residency training in medical oncology. After leading the immunotherapy program at the University of L’Aquila for more than a year he has moved to London in 2020.
Dr Cortellini's efforts and research in immuno-oncology immuno-oncology have been recognized with the Berlucchi Foundation award for the "Best Poster" presented at the XXI AIOM (Italian Association of Medical Oncology) National Congress and the Federico Calabresi award for the "Best publication of the year on a high impact factor international journal" at the 21st Edition of the "Grandangolo in Oncology" in 2019. He was also named the recipient of the third “Annual Young Investigator Award 2020”, by the editors of The Oncologist journal for a manuscript exploring the use of immune-checkpoint inhibitors in patients with pre-existing autoimmune diseases. Dr Cortellini is an AIOM member and a member of the AIOM National Scientific Committee (Mandate: 2020-2021); he also is an ESMO (European Society of Medical Oncology) and SITC (Society for Immunotherapy of Cancer) member and served as an external evaluator for the French National Cancer Institute (INCa). He presented poster/oral communications in several national and international meetings (including ASCO, ESMO and AACR meetings) 
11950302.1 and has authored/co-authored a number of full text publicatio.
Dr Anna Olsson-Brown

Expert panel: Dr Anna Olsson-Brown

Medical Oncology Registrar, Clatterbridge Cancer Centre

Speaker's biography

Dr Anna Olsson-Brown graduated with a BSc (Hons) in Pharmacology, before training in Medicine at the University of Liverpool. She is currently a Medical Oncologist at the Clatterbridge Cancer Centre, Liverpool and a previous MRC Clinical Research Fellow at the University of Liverpool.

 

Dr Olsson-Brown is also the Chair of the Academy of Trainee Doctor Group at the Academy of Medical Royal Colleges and the recent past-Chair of the National Oncology Trainees Collaborative for Healthcare Research (NOTCH). Her clinical interests include the use and toxicities of cancer immunotherapies, and her research is based on understanding the immunological events that occur in the presence of immunotherapy that lead to toxicity. She has established a regional pan-tumour immunotherapy service that supports patients on immunotherapy and those experiencing toxicity and clinically manages patients with toxicity as well as those with melanoma and sarcoma. 

Agenda

View the programme

This meeting is fully funded by Eisai. Content and speakers were chosen by the company. The meeting is intended for healthcare professionals only. Date of preparation: DOP June2021 UK-ONC-21-00065
Welcome and introduction

Chair: Dr David Pinato, Clinical Senior Lecturer and Consultant Medical Oncologist, Chief Investigator of the OnCovid Study, Imperial College London

Adverse events associated with immunotherapy combinations treatment

Chair: Dr David Pinato and then Expert Panel with Dr Alessio Cortellini and Dr Anna Olson-Brown

Case study 1

Dr Alessio Cortellini, Consultant Medical Oncologist University L'Aquila, Italy and Imperial College Hospital, London, Visiting Researcher Imperial College Hospital London

Case study 2

Dr Anna Olsson Brown, Medical Oncology Registrar, Clatterbridge Cancer Centre

Q and A and panel discussion
Closing remarks

Chair: Dr David Pinato

Sponsors

Eisai (1)

Location

Online

This meeting is fully funded by Eisai and is non-promotional. Content and speakers were chosen by the company. The meeting is intended for healthcare professionals only.

Date of preparation: July2021 UK-ONC-21-00065

Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM nor the speaker's organisations. 

Special rates for difficult times  

The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s weekly COVID-19 Series webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic.